Alphamab Oncology Buys Back 115,000 Shares for HKD 0.98 Million, Lifts Treasury Stock to 6.10 Million

Bulletin Express09-01 20:02

Alphamab Oncology disclosed a share repurchase on 1 September 2026, buying back 115,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging between HKD 8.48 and HKD 8.54. The volume-weighted average repurchase price was HKD 8.5133, bringing the total consideration to approximately HKD 0.98 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased marginally by 0.0119% to 968.28 million shares, while the treasury-share balance rose to 6.10 million. The overall issued share count, including treasury shares, remains unchanged at 974.38 million.

The buyback forms part of the mandate approved on 12 June 2026, which authorizes repurchases of up to 96.85 million shares. Cumulative purchases under this mandate now total 225,000 shares, equivalent to 0.0232% of the issued share base on the mandate date. All shares repurchased to date are being held as treasury shares; none have been cancelled.

In accordance with Hong Kong listing rules, Alphamab Oncology is subject to a moratorium on issuing new shares or disposing of treasury shares until 1 October 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193934476?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193934476","market":"hk","top_or_hot":-1,"title":"Alphamab Oncology Buys Back 115,000 Shares for HKD 0.98 Million, Lifts Treasury Stock to 6.10 Million","media":"Bulletin Express","content":"<p>Alphamab Oncology disclosed a share repurchase on 1 September 2026, buying back 115,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging between HKD 8.48 and HKD 8.54. The volume-weighted average repurchase price was HKD 8.5133, bringing the total consideration to approximately HKD 0.98 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) decreased marginally by 0.0119% to 968.28 million shares, while the treasury-share balance rose to 6.10 million. The overall issued share count, including treasury shares, remains unchanged at 974.38 million.</p>\n<p>The buyback forms part of the mandate approved on 12 June 2026, which authorizes repurchases of up to 96.85 million shares. Cumulative purchases under this mandate now total 225,000 shares, equivalent to 0.0232% of the issued share base on the mandate date. All shares repurchased to date are being held as treasury shares; none have been cancelled.</p>\n<p>In accordance with Hong Kong listing rules, Alphamab Oncology is subject to a moratorium on issuing new shares or disposing of treasury shares until 1 October 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alphamab Oncology Buys Back 115,000 Shares for HKD 0.98 Million, Lifts Treasury Stock to 6.10 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlphamab Oncology Buys Back 115,000 Shares for HKD 0.98 Million, Lifts Treasury Stock to 6.10 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-01 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alphamab Oncology disclosed a share repurchase on 1 September 2026, buying back 115,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging between HKD 8.48 and HKD 8.54. The volume-weighted average repurchase price was HKD 8.5133, bringing the total consideration to approximately HKD 0.98 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) decreased marginally by 0.0119% to 968.28 million shares, while the treasury-share balance rose to 6.10 million. The overall issued share count, including treasury shares, remains unchanged at 974.38 million.</p>\n<p>The buyback forms part of the mandate approved on 12 June 2026, which authorizes repurchases of up to 96.85 million shares. Cumulative purchases under this mandate now total 225,000 shares, equivalent to 0.0232% of the issued share base on the mandate date. All shares repurchased to date are being held as treasury shares; none have been cancelled.</p>\n<p>In accordance with Hong Kong listing rules, Alphamab Oncology is subject to a moratorium on issuing new shares or disposing of treasury shares until 1 October 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09966","symbol_name":"康宁杰瑞制药-B","start_time":0,"source_url":"","article_id":"1193934476","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193934476","pubTimestamp":1788264137,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Alphamab Oncology disclosed a share repurchase on 1 September 2026, buying back 115,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging between HKD 8.48 and HKD 8.54. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09966":"康宁杰瑞制药-B"},"translate_title":"康宁杰瑞肿瘤以98万港元回购11.5万股，库存股增至610万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":1},"content_text":"Alphamab Oncology disclosed a share repurchase on 1 September 2026, buying back 115,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging between HKD 8.48 and HKD 8.54. The volume-weighted average repurchase price was HKD 8.5133, bringing the total consideration to approximately HKD 0.98 million.\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) decreased marginally by 0.0119% to 968.28 million shares, while the treasury-share balance rose to 6.10 million. The overall issued share count, including treasury shares, remains unchanged at 974.38 million.\nThe buyback forms part of the mandate approved on 12 June 2026, which authorizes repurchases of up to 96.85 million shares. Cumulative purchases under this mandate now total 225,000 shares, equivalent to 0.0232% of the issued share base on the mandate date. All shares repurchased to date are being held as treasury shares; none have been cancelled.\nIn accordance with Hong Kong listing rules, Alphamab Oncology is subject to a moratorium on issuing new shares or disposing of treasury shares until 1 October 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193934476","isCrawlerRequest":true}